Mobile Logo

EdR Fund Global Healthcare Thematic equities

Thematic equities
Change in NAV (16/08/2017)
327.65 EUR
Adeline  SALAT-BAROUX–LU1160357403–
Adeline SALAT-BAROUX
Valérie GUELFI–LU1160357403–
Valérie GUELFI
The identity of the managers presented in this document may change during the life of the product.
Risk and reward profile (1)
1234567
Recommended holding period
5 years
327.65 EUR
Change in NAV (16/08/2017)
6
1234567
Risk and reward profile
5 years
Recommended holding period
Change in NAV (16/08/2017)
327.65 EUR
Risk and reward profile
1234567
Recommended holding period
5 years
Adeline SALAT-BAROUX  
Valérie GUELFI  
The identity of the managers presented in this document may change during the life of the product.
Contact

Investment objective

The objective is to grow net assets by investing in companies operating in the healthcare sector, over the recommended investment period.

View more View less

Commentary 31/07/2017

After weeks of debate, Republican Senators did not manage to gather enough votes to repeal and reform the Affordable Care Act, raising fresh uncertainties about the US regulatory environment. On the corporate side, Vertex Pharmaceuticals rebounded sharply on publication of very positive results for a triple combination treatment for cystic fibrosis. In contrast, AstraZeneca fell following the disappointing publication of clinical trial results in the treatment of lung cancer. We sold Perkin Elmer, the measuring instruments maker, after a good performance by the stock and the announcement of its acquisition of the German specialist tester, Euroimmun. A position has been initiated on the biotech laboratory, Tesaro, which has a product on the market for the treatment of nausea, and a promising pipeline in the PARP-inhibitor segment. This treatment aims to kill cancer cells by blocking the DNA repair enzyme. Clinical studies are currently underway on this in breast and ovarian cancer.

View more View less

Change in NAV

Chart – Base 100 (16/08/2017)
Avertissement
You are about to download the historical data for a portfolio. Please note that past performance is not an indication of future performance and it may vary over time. They may be affected, for example, by changes in exchange rates


Performance I-EUR Cumulative Annualised
Since 01/01/2017

1.50 %

3.19 %

1.50 %

3.19 %

1 Year

1.94 %

1.30 %

1.94 %

1.30 %

3 Year

37.28 %

38.40 %

11.11 %

11.41 %

5 year

102.49 %

100.83 %

15.15 %

14.96 %

Since inception

227.65 %

234.99 %

15.92 %

16.24 %

Since 01/01/2017 1 Year 3 Year 5 year Since inception
Cumulative

Share class (I-EUR)

Benchmark

1.50 %

3.19 %

1.94 %

1.30 %

37.28 %

38.40 %

102.49 %

100.83 %

227.65 %

234.99 %

Annualised

Share class (I-EUR)

Benchmark

1.94 %

1.30 %

11.11 %

11.41 %

15.15 %

14.96 %

15.92 %

16.24 %

*Rolling periods

Annual performance



Statistics

VolatilityTracking ErrorCorrelation coefficientInformation ratioSharpe ratio
Share class I-EURBenchmarkShare class I-EURBenchmarkShare class I-EURBenchmarkShare class I-EURBenchmarkShare class I-EURBenchmark
1 Year*18.45 %14.41 %5.49 %0.97 %0.32 %-0.04 %
3 Year *16.71 %15.11 %4.06 %0.97 %0.11 %0.80 %
Max. drawdownAlphaBeta
Share class I-EURBenchmarkShare class I-EURBenchmarkShare class I-EURBenchmark
1 Year*-12.39 %0.04 %1.24 %
3 Year *-24.75 %-0.02 %1.08 %
Max. monthly gain Since inception12.57 %
Max. monthly loss Since inception-17.62 %
Share class I-EUR
Benchmark
1 Year* 3 Year * 1 Year* 3 Year *
Volatility 18.45 % 16.71 % 14.41 % 15.11 %
Tracking Error 5.49 % 4.06 %
Sharpe ratio -0.04 % 0.80 %
Alpha 0.04 % -0.02 %
Correlation coefficient 0.97 % 0.97 %
Information ratio 0.32 % 0.11 %
Max. monthly loss -17.62 %
Max. monthly gain 12.57 %
Max. drawdown -12.39 % -24.75 %
Beta 1.24 % 1.08 %

Fund information

Inception Date (Fund)
30/04/1985
Inception Date (Part)
06/08/2009
Legal form
SICAV
Benchmark
MSCI AC World Health Care (NR)
Currency (fund)
EUR
Currency (share class)
EUR
Distribution Policy
Accumulation
Valuation frequency
Daily
Minimum initial investment
500000.00 EUR
ISIN Code
LU1160357403
AuM (fund)
476 M (EUR)
Regulatory authority
CSSF
EU Regulation
UCITS
Management company
Edmond de Rothschild Asset Management (Luxembourg)
Delegated Management Company
Edmond de Rothschild Asset Management (France)
Incorporation
Luxembourg
Maximum management fee
0,750 %
Current management fee
0.750 %
Subscription and redemption conditions
Daily before 12.30 am C.E.T. on day's net asset value
Performance fee
15,000 %

Fund documentation

Select all

(1) The rating grades the funds on a scale from 1 to 7. This rating system is based on the average fluctuations of the net asset value over the past five years. It corresponds to the variation range of the portfolio upwards and downwards. If the net asset value is less than 5 years old, the rating is determined by other regulatory calculation methods. Historical data such as those used to calculate the rating may not be a reliable indication of the future risk profile. The current category is neither a guarantee nor an objective. Category 1 does not signify a risk-free investment.

Top